OC
LUMO

Oppenheimer & Co’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Oppenheimer & Co’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,244
Closed -$114K – 1371
2017
Q3 		$114K Buy
+1,244
New +$95.4K ﹤0.01% 1243
2017
Q1 		– Sell
-1,356
Closed -$125K – 1361
2016
Q4 		$125K Sell
1,356
-277
-17% -$31.2K ﹤0.01% 1217
2016
Q3 		$221K Sell
1,633
-223
-12% -$22.1K 0.01% 1093
2016
Q2 		$188K Sell
1,856
-866
-32% -$107K 0.01% 1106
2016
Q1 		$446K Buy
2,722
+411
+18% +$83.3K 0.01% 797
2015
Q4 		$757K Buy
2,311
+778
+51% +$253K 0.02% 642
2015
Q3 		$495K Buy
1,533
+366
+31% +$161K 0.02% 811
2015
Q2 		$465K Buy
1,167
+334
+40% +$142K 0.01% 912
2015
Q1 		$410K Hold
833
– – 0.01% 967
2014
Q4 		$298K Buy
+833
New +$248K 0.01% 1034

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oppenheimer & Co's LUMO Position: Q4 2017 in Review

Oppenheimer & Co sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2017, closing a stake of 1,244 shares — an estimated $114K sold.

Oppenheimer & Co first reported a position in LUMO in Q4 2014 and held it in 10 quarters. The position peaked at $757K in Q4 2015. 130 funds tracked by Wall St. Rank hold LUMO as of Q4 2017.

  • Oppenheimer & Co reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Oppenheimer & Co sold 1,244 Lumos Pharma, Inc. Common Stock shares in Q4 2017, an estimated $114K.
  • Oppenheimer & Co first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2014 and held it in 10 quarters.
  • Oppenheimer & Co's Lumos Pharma, Inc. Common Stock position peaked at $757K in Q4 2015.
  • 130 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2017.

Based on Oppenheimer & Co's 13F filing for Q4 2017, filed 7 Feb 2018.